SRI International Executives Discuss Drug Discovery & Development at BioJapan 2009 | SRI International

Toggle Menu

SRI International Executives Discuss Drug Discovery & Development at BioJapan 2009


A luncheon seminar will focus on SRI International’s work in cancer research, immunology and inflammation, infectious disease, and neuroscience. SRI executives Walter H. Moos, Ph.D., vice president of SRI’s Biosciences Division, and Nathan Collins, Ph.D., executive director of drug discovery programs in SRI’s Biosciences Division, will discuss special focus areas, including tumor microenvironment, chronic diseases, anti-bacterials and anti-virals, addiction, biomarkers, and drug delivery systems. They will explain how SRI’s Idea to IND™ approach drives an innovative drug discovery program with a strong pipeline of new drugs in various phases of development. Drs. Moos and Collins will also mention pralatrexate (Folotyn™), a drug that SRI and its partners licensed to Allos and which was recently approved by the U.S. Food and Drug Administration for therapy of relapsed or refractory peripheral T-cell lymphoma. The luncheon seminar will include remarks by Osamu Karatsu, Ph.D, executive director of SRI Japan, who will outline the progress the organization has made in the last few years.


Wednesday, October 7, 2009, 12:00 p.m. - 1:00 p.m.


BioJapan Pacifico Yokohama, Exhibition Hall
1-1-1 Minato Mirai
Nishi-ku, Yokohama 220-0012, Japan


Dr. Walter H. Moos, vice president of SRI International’s Biosciences Division, leads a unique team of more than 200 people with all the resources necessary to take chemical and biological research programs from Idea to IND™ — from initial discoveries to investigational new drug applications to start human clinical trials.

During his career, Dr. Moos has made significant contributions to all stages of drug development, from basic research, through preclinical and clinical development, to the marketplace. Prior to joining SRI in 2005, he was Chairman and CEO of MitoKor (now Migenix). Previously, for Chiron (now Novartis) he was a corporate vice president and held positions from Director of Chemical Therapeutics to Vice President of Research and Development in the Technologies Division. He held various positions at the Parke-Davis Pharmaceutical Research Division of Warner-Lambert (now Pfizer), last serving as Vice President, Neuroscience and Biological Chemistry.

Dr. Moos has served on the boards of directors of more than a dozen organizations and is a co-founding member of the CEO Council, advisors to Red Abbey Venture Partners. He has served as a member of a number of academic or government advisory boards and committees. He has also edited five books, helped to found multiple scientific journals, and has more than 150 publications and patents.

Dr. Moos holds a Ph.D. from the University of California-Berkeley and received an A.B. from Harvard University. He has held adjunct faculty positions at the University of Michigan, Ann Arbor, and has been an Adjunct Professor at the University of California, San Francisco since 1992 and at James Madison University since 2007.


Dr. Nathan Collins, executive director of drug discovery programs in SRI’s Biosciences Division, plays a strategic leadership role in SRI’s drug discovery programs, working collaboratively to fund and expand next-generation drug discovery programs.Prior to joining SRI in 2006, Dr. Collins had a long tenure at San Diego-based Discovery Partners (DPI), a small molecule and natural product based drug discovery company that offered collaborations and services complementing the internal capabilities of pharmaceutical and related companies. He has experience in building and strengthening teams to achieve difficult goals, and also has a strong record in business development and government contract funding. Previously, Dr. Collins was a corporate vice president at DPI, and also served as the Steering Committee Co-Chair for a major agreement with Pfizer. Dr. Collins has a Ph.D. and a B.S. from the University of Southampton, U.K. He was a post-doctoral research fellow at the University of Arizona. He also has been an author and inventor on many publications and patent applications. He is a member of the American Chemical Society, the Society for Biomolecular Screening, and the Product Development and Management Association.

VISUALS PowerPoint presentation

To register for the seminar, please contact:  biosciences [at] sri.comFor more information about BioJapan 2009, please visit:

Media Contact:
Lindsay Sheppard
SRI International
Corporate & Marketing Communications
lindsay.sheppard [at]

Centers & Labs: